Callodine Capital Management LP Purchases 109,240 Shares of Sanofi $SNY

Callodine Capital Management LP grew its holdings in Sanofi (NASDAQ:SNY) by 26.9% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 515,209 shares of the company’s stock after purchasing an additional 109,240 shares during the quarter. Sanofi comprises 2.6% of Callodine Capital Management LP’s portfolio, making the stock its 15th biggest holding. Callodine Capital Management LP’s holdings in Sanofi were worth $24,890,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in SNY. Ameritas Advisory Services LLC acquired a new stake in Sanofi in the 2nd quarter valued at approximately $28,000. Banque Transatlantique SA bought a new stake in shares of Sanofi in the first quarter valued at approximately $33,000. Concord Wealth Partners boosted its position in shares of Sanofi by 510.3% in the second quarter. Concord Wealth Partners now owns 885 shares of the company’s stock valued at $43,000 after acquiring an additional 740 shares during the period. Nisa Investment Advisors LLC grew its stake in shares of Sanofi by 233.3% in the second quarter. Nisa Investment Advisors LLC now owns 1,000 shares of the company’s stock worth $48,000 after acquiring an additional 700 shares during the last quarter. Finally, Traub Capital Management LLC bought a new position in Sanofi during the second quarter worth $51,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on SNY. Jefferies Financial Group reissued a “buy” rating on shares of Sanofi in a report on Monday, October 27th. Morgan Stanley upgraded Sanofi from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $56.00 to $58.00 in a research note on Monday, September 8th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Sanofi in a report on Monday, December 1st. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $62.67.

Sanofi Stock Performance

NASDAQ:SNY opened at $49.53 on Friday. The firm has a market capitalization of $121.62 billion, a PE ratio of 11.60, a price-to-earnings-growth ratio of 1.35 and a beta of 0.44. The company has a quick ratio of 0.30, a current ratio of 1.06 and a debt-to-equity ratio of 0.16. Sanofi has a 12-month low of $44.62 and a 12-month high of $60.12. The firm has a 50-day moving average price of $49.90 and a 200 day moving average price of $49.18.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Friday, October 24th. The company reported $2.91 earnings per share for the quarter, beating the consensus estimate of $1.60 by $1.31. The company had revenue of $15.46 billion for the quarter, compared to analyst estimates of $12.62 billion. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The company’s revenue was down 7.5% compared to the same quarter last year. During the same period in the prior year, the company posted $2.25 EPS. Research analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.